Interaction of hemostatic genetics with hormone therapy: New insights to explain arterial thrombosis in postmenopausal women

Joel B. Braunstein, Dawn Warner Kershner, Paul Bray, Gary Gerstenblith, Steven P. Schulman, Wendy S. Post, Roger S. Blumenthal

Research output: Contribution to journalReview article


Genetic variants of key hemostatic mediators increasingly have been proposed as risk factors for atherothrombosis. The Hormone and Estrogen/Progestin Replacement Study group recently reported that the initiation of estrogen replacement in postmenopausal women with known coronary heart disease is associated with an early increase in cardiovascular events. A putative genetic susceptibility factor has been proposed a potential mediator of this increased event risk. This review outlines the recent literature to support the premise for this important proposal. Genetic profiling has great potential to improve the safety and efficacy of individualized pharmacotherapy in postmenopausal women and other at-risk populations for the prevention of cardiovascular disease.

Original languageEnglish (US)
Pages (from-to)906-920
Number of pages15
Issue number3
StatePublished - Jan 1 2002



  • Arterial thrombosis
  • Estrogen therapy
  • Genetic polymorphisms
  • Hemostatic factors

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Critical Care and Intensive Care Medicine
  • Cardiology and Cardiovascular Medicine

Cite this